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Abstract: 18-flurodesoxyglucose position emission tomography (FDG-PET) with computed tomography
(CT) or magnetic resonance imaging (MRI) is a broadly accepted tool for pretherapeutic staging and
post-therapeutic assessment of response. The prognostic value of sequential post-therapeutic FDG-PETs
and the impact of change in metabolic activity has been scarcely reported so far. We hypothesized
that an increase in metabolic activity (as measured by maximum standardized uptake value, SUVmax)
would be predictive for recurrence. We retrospectively assessed all oral, oropharyngeal, laryngeal, and
hypopharyngeal squamous cell carcinoma patients treated at the Department of Otorhinolaryngology—
Head and Neck Surgery, University Hospital Zurich between April 1st, 2010 and September 30th, 2018
(N = 337). After a negative post-treatment FDG-PET at 3 months, we measured the SUVmax of the
local tumor area and the regional lymph nodes on follow-up FDG-PET at 9 months. We then correlated
SUVmax difference between 9 and 3 months with tumor recurrence using Kaplan Meier analysis. During
follow-up, 68 patients (20.2%) had local recurrence and 53 had regional recurrence (15.7%) at a median
time of 9.0 (IQR 4.25–14) and 7.0 (IQR 5.25–23) months, respectively. An increase in local and/or
regional SUVmax from the 3 months to the 9 months post-therapeutic FDG-PET resulted in a poorer
recurrence-free survival (Log rank, <jats:italic>P</jats:italic> = 0.001, for both). An increase in local
SUVmax between 3 and 9 months was associated with a hazard ratio of 4.17 for recurrence (95%CI 1.89–
9.2, <jats:italic>P</jats:italic> = 0.0003). In conclusion, an increase in metabolic activity/SUVmax
between two post-therapeutic FDG-PETs requires a histological examination as it is associated with
tumor recurrence.
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predictive value of suvmax 
changes between two sequential 
post‑therapeutic fDG‑pet in head 
and neck squamous cell carcinomas
thomas M. Stadler1,2, Martin W. Hüllner2,3, Martina A. Broglie1,2 & Grégoire B. Morand1,2*
18-flurodesoxyglucose position emission tomography (FDG-PET) with computed tomography (CT) or 
magnetic resonance imaging (MRI) is a broadly accepted tool for pretherapeutic staging and post-
therapeutic assessment of response. the prognostic value of sequential post‑therapeutic fDG‑pets 
and the impact of change in metabolic activity has been scarcely reported so far. We hypothesized 
that an increase in metabolic activity (as measured by maximum standardized uptake value, 
SUVmax) would be predictive for recurrence. We retrospectively assessed all oral, oropharyngeal, 
laryngeal, and hypopharyngeal squamous cell carcinoma patients treated at the Department of 
Otorhinolaryngology—Head and Neck Surgery, University Hospital Zurich between April 1st, 2010 and 
September 30th, 2018 (N = 337). After a negative post-treatment FDG-PET at 3 months, we measured 
the SUVmax of the local tumor area and the regional lymph nodes on follow-up FDG-PET at 9 months. 
We then correlated SUVmax difference between 9 and 3 months with tumor recurrence using Kaplan 
Meier analysis. During follow-up, 68 patients (20.2%) had local recurrence and 53 had regional 
recurrence (15.7%) at a median time of 9.0 (IQR 4.25–14) and 7.0 (IQR 5.25–23) months, respectively. 
An increase in local and/or regional SUVmax from the 3 months to the 9 months post-therapeutic FDG-
PET resulted in a poorer recurrence-free survival (Log rank, P = 0.001, for both). An increase in local 
SUVmax between 3 and 9 months was associated with a hazard ratio of 4.17 for recurrence (95%CI 
1.89–9.2, P = 0.0003). In conclusion, an increase in metabolic activity/SUVmax between two post-
therapeutic fDG‑pets requires a histological examination as it is associated with tumor recurrence.
18-fluorodeoxyglucose positron emission tomography (FDG-PET) with computed tomography (CT) or mag-
netic resonance (MR) imaging has become a broadly accepted imaging tool in routine clinical oncology. Adding 
FDG-PET to the staging process results in improved nodal classification, detection of distant metastases, and 
contralateral nodal  disease1–3. FDG-PET is also a valuable asset for primary tumor identification in patients with 
carcinoma of unknown primary (CUP) of the head and  neck4. FDG-PET can also be used as response assessment 
in the post-therapeutic setting, as a negative FDG-PET after chemoradiation can exclude with a high negative 
predictive value (NPV) residual locoregional  disease5,6. Quantitative assessment of metabolic activity by e.g. 
maximum standardized uptake value  (SUVmax) is in turn useful for identifying tumors with a more aggressive 
phenotype and hence patients that may require more intensive treatment  protocols7–10.
In the post-treatment surveillance setting, there are no internationally defined follow-up imaging strategies 
and they differ widely between institutions and  countries11,12. The normal anatomy of the head and neck becomes 
distorted by surgery and/or chemoradiation. Distinguishing residual or recurrent tumor from treatment related 
changes is often virtually impossible on anatomical imaging studies such as CT and  MRI13. At our institution, it 
has become our internal policy to perform posttherapeutic FDG-PETs at three months and at nine months after 
definitive treatment for patients with advanced stage disease.
While the value of a single FDG-PET in the pretherapeutic and posttherapeutic setting has been described, 
the prognostic value of changes in metabolic activity on sequential posttherapeutic FDG-PETs has been scarcely 
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reported so far. We hypothesized that, after a negative posttherapeutic FDG-PET at three months, an increase 
in metabolic activity during follow-up was associated with tumor recurrence, whereas the metabolic activity of 
post-therapeutic inflammatory changes would decrease over time.
Materials and methods
Study population. After local ethics review board approval by the Kantonale Ethikkommission Zürich, we 
retrospectively assessed all patients with squamous cell carcinoma of the oral cavity, oropharynx, larynx, and 
hypopharynx treated at the Department of Otorhinolaryngology – Head and Neck Surgery of the Zurich Uni-
versity Hospital, Zurich, Switzerland between April 1st 2010 and September 30th, 2018. Study methods were 
carried out in accordance with the relevant guidelines and regulations. Informed consent was obtained from 
all subjects. Inclusion criteria were available pre-therapeutic FDG-PET/CT or FDG-PET/MR images as well as 
post-therapeutic FDG-PET/CT or FDG-PET/MR. According to our institutional policy, pretherapeutic FDG-
PET was obtained for all patients with advanced stage disease (stage III / IV, ≥ T3, ≥ N2a/b). However, we also 
included a few patients with < T3 or < N2a referred externally with an already available FDG-PET. After comple-
tion of treatment, posttherapeutic FDG-PETs were performed at three and nine months of follow-up (Fig. 1). 
The study cohort was then divided into four groups according to tumor site, analyzing oral, oropharyngeal, 
laryngeal, and hypopharyngeal cancer separately. Patients without further imaging after initial diagnosis were 
excluded. Only patients treated in curative intent were included.
All patients were staged according to the Union Internationale Contre le Cancer (UICC), TNM staging for 
head and neck cancer, 7th edition,  201014. All cases were discussed at the local interdisciplinary tumor board 
and treated according to the NCCN  Guidelines15.
Detailed data on age, gender, tumor subsite, and risk factors including smoking, drinking habits, and human 
papilloma virus (HPV) status were obtained. In oropharyngeal cancer, immunohistochemical expression of 
p16 was assessed and in positive cases polymerase chain reaction (PCR) for HPV was used to evaluate HPV 
status of tumor biopsy  samples16. Tobacco use was defined as a current daily consumption or history of daily 
consumption of cigars or cigarettes. Alcohol abuse was defined as a daily intake of more than 20 g of ethanol at 
least five days a  week17.
FDG-PET/CT or -/MR acquisition. Detailed FDG-PET acquisition protocol have been reported 
 previously18. After a fasting time of at least four hours, patients were injected with a standardized dose of 3.5 MBq 
of FDG per kilogram body weight (PET/CT) or 3.0 MBq per kg body weight (PET/MR), and from 2017 on with 
a body mass index-adapted, body weight-dependent dosage protocol for PET/MR19. All doses were prepared an 
injected with an automatic PET infusion system (Medrad Intego, Bayer Healthcare), the prescribed dose was met 
by ± 5% in all subjects. Glucose level was measured and ranged 4–12 mmol/l before imaging.
Resting time after injection was one hour. During this period, patients were advised to remain in lying posi-
tion without talking in order to minimize muscular FDG uptake. All subjects met the uptake time of 60 min + /- 
5 min. Patients were kept warm prior to tracer injection and throughout the uptake period to diminish FDG 
accumulation in brown adipose tissue. Most patients received either iodinated or gadolinium-based contrast 
medium. An integrated Discovery VCT PET/CT system (GE Healthcare, Waukesha, WI, USA), a Discovery PET/
CT 690 (GE Healthcare), or a hybrid PET/MRI system (Signa PET/MR, GE Healthcare) was used for image acqui-
sition. All PET images were reconstructed with the same algorithm (ordered subset expectation maximization).
For attenuation correction in PET/CT, transmission data from a standard low-dose CT scan was used. For 
attenuation correction in PET/MR, a two-point Dixon-type three-dimensional (3D) gradient dual-echo MR pulse 
sequence (Liver acquisition with volume acceleration, LAVA-flex) was  used20. All images used for attenuation 
correction were without i.v. contrast material.
The regionalized anatomical CT and MR imaging protocol for the head and neck used standard acquisition 
parameters for head and neck imaging, including adapted field of view (e.g., MR field of view range: 24 to 50 cm, 
depending on respective pulse sequence) and increased matrix size (e.g., MR matrix size range: 256 × 192 to 
320 × 256 pixels, depending on respective pulse sequence), as published  previously20.
CT emission data were iteratively reconstructed (matrix size 256 × 256 pixels, 3D TOF ordered subset expec-
tation maximization (OSEM) with 3 iterations and 18 subsets, with point spread function, 4.7 mm full width at 
half maximum, 1:4:1 weighted axial filtering.
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Figure 1.  Graphical representation of pre- and post-treatment algorithm at our clinic. Upon referral, 
patients received triple endoscopy. FDG-PET is obtained as indicated. Patient are treated according to our 
multidisciplinary tumor board decision. After definitive therapy, patients enter post-therapeutic follow-up for 
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The  SUVmax of the primary tumor was obtained under supervision of a dually board-certified nuclear medi-
cine physician/radiologist (MWH). Moreover, in patients with clinically positive nodal status, the  SUVmax of the 
dominant (that is with the highest  SUVmax) lymph node was recorded as well.  SUVmax was calculated automati-
cally using a standard formula [maximum activity in region of interest ÷ (injected dose × body weight)]. Correct 
analysis of FDG uptake was ensured through side-by-side reading of the corresponding CT or MR images of the 
tumor in the axial, coronal, and sagittal plane. Borders of regions of interest (ROI) were set by manual adjustment 
to exclude adjacent physiologic FDG-avid structures.
Primary analysis (Fig. 2). For the primary outcome analysis, we included all patients in the analysis. Local 
recurrence was defined as presence of tumor confirmed by histopathology in the primary tumor site after com-
pletion of curatively intended treatment. Regional recurrence was defined by cytologically and/or histologically 
confirmed presence of malignant disease in the cervical lymph nodes after completion of curatively intended 
treatment. Time to local and regional recurrence was calculated in months from the completion of curative 
therapy (time zero) unto the date of histological or cytological proof of local or regional recurrence.
All metachronous tumors had to be confirmed by histopathology and had a location different from the pri-
mary tumor for which the patients were treated. Time to metachronous tumor was calculated in months from the 
completion of curative therapy (time zero) unto the date of histological or cytological proof of second primary.
Secondary analysis (Fig. 2). Analysis of sequential posttherapeutic FDG-PET. For the secondary out-
come analysis, we aimed to evaluate the prognostic value of the second posttherapeutic FDG-PET done at 
9 months after completion of treatment. Therefore, we only included patients showing a recurrence detected by 
the second posttherapeutic FDG-PET at 9 months. Median time difference between the end of treatment and 
first posttherapeutic FDG-PET at 3 months was 92.5 days (IQR 83 – 111.5). Median time difference between end 
of treatment and second posttherapeutic FDG-PET after nine months was 261.5 days (IQR 239.75 – 277). The 
median time difference between the second FDG-PET at nine months and pathological confirmation of tumor 
recurrence was 41 days (IQR 22.5 – 86).
Therefore, to accommodate for slight variations when calculating the time to recurrence and owing to slight 
variations in the timing of three months and nine months FDG-PET, we included all recurrences recorded to 
occur between 8 and 14 months after completion of treatment (time zero). All recurrences occurring before and 
after this time frame were excluded from the secondary analysis.
All patients included in the secondary analysis therefore had showed a complete metabolic response (score 
of two or less according to the Hopkins criteria)21 on the first posttherapeutic FDG-PET at three months after 
completion of treatment. These patients were then followed-up clinically, another FDG-PET was acquired at nine 
months. We then assessed the  SUVmax of the local tumor area and dominant regional lymph node on the FDG-
PET at nine months after completion of treatment. The  SUVmax at three months was subtracted from the  SUVmax at 
nine months. The difference (> 0 – increase vs. ≤ 0 – decrease-stable) was then correlated with recurrences (local 
and regional, respectively) occurring or detected after the second post-therapeutic FDG-PET at nine months.
121 locoregional recurrences (35.9%)
337 head and neck squamous cell carcinoma patients 
with available pre- and posttherapeutic FDG-PET
- 45 Oral cancer
- 198 Oropharyngeal cancer
- 38 Laryngeal cancer
- 55 Hypopharyngeal cancer
51 metachronous tumors (15.1%)
Primary analysis Secondary analysis 
249 patients with negative first posttherapeutic 
FDG-PET (3 months)
Second posttherapeutic FDG-PET (9 months)
Comparison of SUVmax of primary 
tumor and dominant lymph node on 
posttherapeutic FDG-PET at 9 and 3 
months
Figure 2.  Flow chart showing how patients were included in the primary and secondary analysis.
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Statistical analysis. For continuous variables, distribution was evaluated for normality according to Gauss’ 
 theorem22. For non-normally distributed variables, median and interquartile range (IQR) are given. For nor-
mally distributed variables, mean and standard deviation (SD). To compare the distribution among samples, the 
one-way ANOVA and the non-parametric Kruskal–Wallis test were used for continuous variables, according to 
their distribution (normal vs. non-normal, respectively). For nominal variables, the chi-square test was used. 
Main outcome measures of the study were calculated using a Cox regression model. Results are expressed in 
hazard ratio (HR) with the 95% confidence interval provided (95% CI). Survival curves were built according 
to the Kaplan–Meier method. The log-rank test was performed to compare survival among factors. A P-value 
lower than 0.05 was considered to indicate statistical significance. Statistical analyses were performed using SPSS 
25.0.0.0 software (IBM, Armonk, NY, USA).
Results
patient and tumor characteristics. A total of 337 consecutive patient were included. The mean age at 
diagnosis was 66 (SD 11.2). Patients were predominantly male (248/337, 73.6%). Forty-six (13.6%) had oral cav-
ity cancer, while 198 (58.8%), 38 (11.3%), and 55 (16.3%) had oropharyngeal, laryngeal, and hypopharyngeal 
cancer, respectively. Overall, 264 out of 337 (78.8%) of the patients had advanced disease; 179 patients (53.1%) 
had cT3-cT4 tumors in comparison to 158 (46.9%) of patients with cT1-cT2 tumors. Clinical nodal status was 
positive in 232 patients (68.8%), of which 91 were staged cN1 (27.0%), 76 cN2a-b (22.5%) and 65 cN2c-cN3 
(19.2%). Median follow-up time for all patients was 22.0 months (IQR 10 – 40). Most patients received primary 
chemoradiation (67.9%, 229/337), whereas 108 patients were treated surgically with (55.5%, 60/108) or without 
(44.5%, 48/108) adjuvant radiation (32.1%, 108/337) (Table 1).
Primary analysis. Pattern and timing of recurrences. In the whole study cohort (n = 337), there were 121 
locoregional recurrences (35.9%), of whom 68 (20.2%) had local recurrence and 53 (15.7%) had a regional 
recurrence. The median time to local recurrence was 9.0 months (IQR 4.25 – 14). The median time to regional 
recurrence was 7.0 months (IQR 5.25–23) (Supplemental Figs. 1 and 2). The vast majority of local and regional 
recurrences occurred in the first 24 months after completion of treatment (Table 2).
When comparing local and regional recurrence by site, there was a highly significant difference in tumor 
recurrence (Log rank test, P = 0.001 and P = 0.032, respectively). Oropharyngeal cancer had the lowest local 
recurrence rate, meanwhile hypopharyngeal had the highest local recurrence rate, while laryngeal carcinoma 
had the lowest regional recurrence rate. (Fig. 3, Panel A and B).
Rate of metachronous primary tumors. We then assessed the rate of second metachronous primaries and plot-
ted them against time (Supplemental Fig. 3). There were 51 cases of metachronous tumors (15.1%), 45 in smok-
ers (13.3%), and six in non-smokers (1.8%). This difference was statistically significant (HR 2.86, 95%CI 1.17–
6.9, P = 0.015). Smokers had therefore can approximately three times higher likelihood to develop metachronous 
primary tumors.
Secondary analysis. Local  SUVmax temporal changes. We then evaluated the predictive value of two se-
quential posttherapeutic FDG-PETs. Figure 4 exemplifies two patients with complete metabolic response at three 
months (Hopkins < 2). In the first patient (Fig. 4, Panel A-C), the  SUVmax at nine months slightly increased (from 
4.1 to 5.7, 39.0% increase). Histopathological analysis revealed local recurrence. In the second patient (Fig. 4, 
Panel D-F),  SUVmax decreased between three and nine months FDG-PET (from 4.0 to < 1 100% decrease). This 
patient remained free of disease.
Overall, there were 22 local recurrences recorded in the time frame for the secondary analysis (see methods). 
When assessing the local  SUVmax changes between three and nine months, statistical analysis revealed that an 
increase in  SUVmax of the primary tumor area between the second and first post-therapeutic FDG-PET pre-
dicted a higher risk of local recurrence (Fig. 5, Panel A, Log rank test, P < 0.001). For disease-specific survival, 
the difference in survival was not significant if local SUVmax increased or decreased between 9 and 3 months 
FDG-PET (Log rank test, P = 0.155).
Using Cox-regression analysis, we calculated that an increase in local  SUVmax between three and nine months 
results in a higher chance for recurrence with a HR 4.17 (95%CI 1.89–9.2, P = 0.0003).
Of the patients with local recurrence detected following the second post-therapeutic FDG-PET, 12/22 patients 
(54.5%) received salvage surgery of their local recurrence. Three (30.0%) of the ten patients without salvage 
surgery died shortly after the diagnosis of recurrence. One patient had tumor bleeding, one pneumonia and 
the third died at home without further information. Three patients (30.0%) had bilateral lung metastases. Four 
(40.0%) had tumors that were inoperable.
Four patients had local and regional recurrence and all these patients underwent successful salvage surgery.
Regional  SUVmax temporal changes. We further evaluated regional recurrences occurring after the second 
posttherapeutic FDG-PET and examined the changes of metabolic activity of the dominant node between the 
second and the first posttherapeutic FDG-PET, at nine and three months, respectively. Overall, there were 14 
regional recurrences recorded in the time frame for the secondary analysis (see methods).
An increase in  SUVmax of nodal disease between the second and first post-therapeutic FDG-PET predicted a 
higher risk of regional recurrence (Log rank test, P < 0.001) (Fig. 5, Panel B).
For disease-specific survival, the difference in survival was not significant if regional SUVmax increased or 
decreased between 9 and 3 months FDG-PET (Log rank test, P = 0.308).
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Of the 14 patients who suffered regional recurrence in the defined interval after the second post-therapeutic 
FDG-PET, six (42.8%) were treated with salvage surgery. The remaining eight (57.2%) patients received chemo-
therapy due to simultaneous distant metastases. All eight patients had bilateral lung metastases, three had addi-
tional bone metastases and one brain metastases as well.
Table 1.  Patient demographics and clinical characteristics. SD: standard deviation; IQR: interquartile range; 
IHC: immunohistochemistry; n/a: not available; RT: Radiotherapy. ANOVA normally distributed variables. 
Kruskal–Wallis test for non-normally distributed continuous variables. Chi-square test for nominal variable. 
Log-rank test for time-dependent variable (local and regional recurrence).
Variable All patients N = 337 Oral N = 46 Oropharynx N = 198 Larynx N = 38 Hypopharynx N = 55
P value (Oral vs. 
Oropharynx vs. Larynx 
vs. Hypopharynx)
Age
Years Mean (SD) 66 (11.2) 60 (15.6) 69 (10.1) 63 (8.9) 64 (9.6) 0.001
Gender
Male n (%) 248 (73.6%) 30 (65.2%) 139 (70.2%) 31 (81.6%) 48 (87.3%)
0.025
Female n (%) 89 (26.4%) 16 (34.8%) 59 (29.8%) 7 (18.4%) 7 (12.7%)
Smoking
Yes (%) 252 (74.8%) 28 (60.9%) 102 (51.5%) 37 (97.4%) 53 (96.4%)
 < 0.001
No (%) 85 (25.2%) 18 (39.1%) 96 (48.5%) 1 (2.6%) 2 (3.6%)
Pack years Median (IQR) 45 (30 – 60) 46.5 (30 – 60) 45 (30 – 60) 54 (40 – 80) 40 (25–62.5)  < 0.001
Alcohol abuse Yes (%) 137 (40.7%) 25 (54.3%) 130 (65.7%) 19 (50.0%) 26 (47.3%)
0.038






cT1 – cT2 n (%) 158 (46.9%) 27 (58.7%) 93 (46.9%) 15 (39.5%) 23 (41.8%)
0.004
cT3 – cT4 n (%) 179 (53.1%) 19 (41.3%) 105 (53.1%) 23 (60.5%) 32 (58.2%)
N-classification
N0 n (%) 105 (31.2%) 24 (52.2%) 51 (25.7%) 20 (52.6%) 10 (18.2%)
 < 0.001
N1 n (%) 91 (27.0%) 7 (15.2%) 73 (36.9%) 4 (10.5%) 7 (12.8%)
N2a – N2b n (%) 76 (22.5%) 10 (21.7%) 42 (21.2%) 5 (13.2%) 19 (34.5%)
N2c – N3 n (%) 65 (19.3%) 5 (10.9%) 32 (16.2%) 9 (23.7%) 19 (34.5%)
Therapy
Surgery n (%) 48 (14.3%) 18 (39.1%) 29 (14.6%) 0 (0.0%) 1 (1.8%)
 < 0.001Surgery + RT n (%) 60 (17.8%) 27 (58.7%) 30 (15.2%) 0 (0.0%) 3 (5.5%)
Radiotherapy n (%) 229 (67.9%) 1 (2.2%) 139 (70.2%) 38 (100%) 51 (92.7%)
Recurrence
Local n (%) 68 (20.1%) 12 (26.1%) 15 (7.5%) 12 (31.5%) 29 (52.7%) 0.001
Regional n (%) 53 (15.7%) 15 (32.6%) 20 (10.1%) 5 (13.1%) 13 (23.6%) 0.032
Time to recurrence (months)
Local Median (IQR) 9 (4.2 – 14) 6.5 (4 – 25) 9 (6 – 12) 9 (5.5 – 14.7) 12 (4.5 – 14.5) 0.810
Regional Median (IQR) 7 (5.2 – 23) 7 (4 – 7) 6 (5 – 12) 17 (6 – 26) 14 (6.5 – 22.5) 0.105
Follow up Median (IQR) 22 (10 – 40) 32.5 (16.7 – 52.2) 16 (7 – 27.7) 31 (22.2 – 62.5) 29 (20 – 57) 0.001
Table 2.  Time of recurrence.
Local recurrence Regional recurrence
Within 12 months 41/68 (60.3%) 32/53 (60.4%)
Within 24 months 60/68 (88.2%) 41/53 (77.4%)
Within 36 months 65/68 (95.6%) 49/53 (92.5%)
Within 48 months 66/68 (97.1%) 50/53 (94.3%)
Within 60 months 68/68 (100%) 53/53 (100%)
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Discussion
In this retrospective analysis of patients with head and neck cancer, we show that, after a negative first postthera-
peutic FDG-PET, an increase in  SUVmax of the primary tumor and/or lymph node is associated with an increased 
risk of recurrence. Second, we show that the vast majority of local and regional recurrences occur within two 
years after completion of treatment, while the occurrence of metachronous second primaries does not fade over 
time if exposure to risk factors is present.
Our locoregional recurrence rates of about one third of patients is within the range reported in the literature. 
These vary between 20–50% depending on primary tumor location and  stage23–25. We included only patients with 
available pretherapeutic FDG-PET, i.e., with advanced stage, according to our internal policy. The median time 
to local and regional recurrence was 9.0 and 7.0 months, respectively. Based on this timing and based on the rate 
of recurrences, we argue that a close monitoring in the first two years is of paramount importance.
Figure 3.  Kaplan–Meier analysis showing local recurrence-free (A) and regional recurrence-free survival (B) in 
patients according to primary tumor site, respectively. Both survival rates were different in a statistically highly 
significant manner (Log rank, P = 0.001 and P = 0.032, respectively).
Figure 4.  Representative axial fused FDG-PET/CT images demonstrating  SUVmax changes in patients with 
head and neck carcinoma. The first patient had hypopharyngeal carcinoma and received chemoradiation. 
After initial decrease of  SUVmax between the pretherapeutic scan (A) and the first post-therapeutic FDG-
PET (3 months) (B), there was an increase in  SUVmax in the second post-therapeutic FDG-PET (9 months) 
(C). Local recurrence was confirmed by histopathology following the 9 months FDG-PET. Other example of 
oropharyngeal cancer patient.  SUVmax decreased between the pretherapeutic (G), first FDG-PET after 3 months 
(H) to a similar level as shown in the first patient (Panel A and B). In the second post-therapeutic FDG-PET, 
however,  SUVmax of primary tumor area further decreased. Patient is free of disease upon last follow-up.
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Hypopharyngeal carcinoma had the highest local recurrence rate followed by laryngeal carcinoma. For 
regional recurrence, hypopharyngeal and oral cavity carcinoma had the highest rate, followed by laryngeal car-
cinoma. However, it should be mentioned that hypopharyngeal carcinoma was the site with the most advanced 
disease at presentation. Interestingly, patients with oral cancer had a less advanced disease stage at diagnosis, 
but had a high rate of regional recurrence. Again, the rate of local and regional recurrences in the literature var-
ies widely among different primary tumor locations and initial stage, with the worst outcome typically seen in 
hypopharyngeal carcinoma, as in our  study26.
The risk of developing a metachronous second carcinoma turned out to be almost constant over the time after 
treatment of the first tumor. In our cohort, 47/337 patients (13.9%) developed a metachronous second primary 
carcinoma within 60 months. In the literature this rate varies between 7 – 15% after five  years27–29.
The risk of a second primary was much higher in smokers, indicating that this population might benefit from 
prolonged follow-up. Whether this strategy leads to significant survival improvement remains hypothetical. 
Further, our data does not allow us to recommend any intensified imaging surveillance scheme in the post-
therapeutic setting. In analogy to what was shown for lung cancer screening, intensified surveillance may result 
in a survival benefit in high-risk groups, while it may be associated with a high rate of false-positive findings and 
an unnecessary exposure to ionizing  radiation30,31.
For patients without exposure to extrinsic carcinogens, it could be discussed whether intensive post-treatment 
surveillance may be limited to 24 months, since most recurrences are diagnosed within this interval.
We show in a secondary analysis that an increase in  SUVmax locally and regionally between two sequential 
posttherapeutic FDG-PETs is associated with a high risk of recurrence. An increase in  SUVmax is therefore associ-
ated with a high suspicion of recurrent tumor.
If biopsies taken in this context are negative, false-negative results due to sampling error have to be ruled 
out. We observed only a few patients (10.6% local (36/337) and 7.7% regional (26/337)) with increasing  SUVmax 
without proof of tumor recurrence. A constant or decreasing  SUVmax on the other hand may be explained by 
inflammation and/or radionecrosis. The latter is sometimes very hard to distinguish from tumor recurrence on 
cross-sectional imaging alone. A previous study by our group showed that a combination of low  SUVmax and 
location of the hottest voxel inside bone/cartilage enables differentiation from tumor  recurrence32.
It should be noted that we intentionally used a rather hard cutoff (increase > 0 vs. stable/decrease ≤ 0) when 
performing our analysis. This provides clinicians a simple and easy rule for daily practice. However, although 
remaining unproven, one can assume that the risk of recurrence would be higher for a larger increase rather than 
a marginal increase of SUVmax. Interpretation in clinical context remains therefore necessary.
For the secondary analysis in which recurrence was detected following the second posttherapeutic FDG-PET 
at nine months, the majority of patients (22/40 (55.0%)) qualified for salvage surgery, meaning that the strategy 
of close follow-up with imaging is valuable. This rate compares favorably with salvage eligibility rates reported 
by other studies (23% to 38%)23,33–35. This finding, however, has to be interpreted with caution as eligibility for 
salvage surgery strongly depends on the primary tumor site, with the larynx being the site most often eligible 
for salvage  surgery26. Previous studies did not report however on their imaging protocol during posttreatment 
surveillance. We assume that these did not include FDG-PET on regular intervals. Whether our higher salvage 
eligibility rate can be explained by FDG-PET monitoring remains unproven and should be investigated in future 
studies. This represents a limitation of our study. Although SUVmax uniquely identifies patients with recurrent 
disease, we did not show that FDG-PET provides information not obtainable by anatomic imaging (CT or MRI) 
alone.
Further, analysis of disease-specific survival showed no significant difference in patients with increasing vs. 
decreasing/stable SUVmax locally and regionally. This can be interpreted as lack of relevance of our findings, 
since increased SUVmax, although predicting local or regional recurrence, does not predict survival. However, 
Figure 5.  Kaplan–Meier analysis showing local recurrence-free (A) and regional recurrence-free survival (B) 
in patients according to tumor site. Both relative recurrence-free survivals were different in a statistically highly 
significant manner (Log rank, P = 0.001, for both).
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maintaining high locoregional control rates are very important to avoid disfigurement, pain, and distress associ-
ated with locoregional failure.
Further limitations of our study need to be mentioned. First, it is a single center study and only one reader 
made the measurements, albeit in a standardized fashion, of FDG-PET metabolic parameters. This introduces a 
selection bias and reduces the external validity of the study. Second, we had a limited number of events and many 
censored events. This limits the strength of the statistical analysis, as we were not able to control for potential 
confounder (HPV status, extra nodal extension, etc.) in a multivariable analysis. Due to its retrospective design, 
the timing and interval of FDG-PET was slightly variable. We addressed this issue by allowing for a longer 
period of recurrence (between 8 and 14 months) for the secondary analysis. Further, we included all tumor 
sites of the head and neck except the nasopharynx and sinonasal area, which needs to be remembered when 
interpreting the salvages rates. Finally, we only measured SUVmax measurements of local tumor and dominant 
lymph node. Further parameters such as total lesion glycolysis (TLG) or metabolic tumor volume (MTV) were 
not assessed. However, in previous  studies8–10 we showed that SUVmax was the metabolic parameters with the 
strongest predictive value.
conclusion
An increase in local and regional  SUVmax between three and nine months after therapy is associated with an 
increased risk of tumor recurrence.  SUVmax changes are a reliable tool for detecting tumor recurrence.
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